MaaT Pharma Appoints Nathalie Corvaïa as Chief Scientific Officer and Strengthens its R&D Activities in Immuno-Oncology - Seite 3

Forward-looking Statements

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

¹ aGVHD = acute Graft-versus-Host Disease
² Allo-HSCT = Allogeneic hematopoietic stem cell transplantation
³ AI : Artificial intelligence

View source version on businesswire.com: https://www.businesswire.com/news/home/20221004005754/en/

The MaaT Pharma Stock at the time of publication of the news with a fall of -1,72 % to 8,02EUR on Frankfurt stock exchange (04. Oktober 2022, 09:16 Uhr).